8 results about "Positive inotropism" patented technology

This invention belongs to the field of biomedical technology, specifically involving Trmt61a The application of genes in the preparation of drugs for treating pathological myocardial hypertrophy. This invention provides... Trmt61a The application of genes in the preparation of drugs for treating pathological myocardial hypertrophy, the aforementioned Trmt61a The nucleotide sequence of the gene is shown in SEQ ID NO.1. Animal experiments have shown that knocking down... Trmt61a Gene knockdown can significantly improve cardiac contractile function after aortic arch coarctation surgery, alleviate cardiomyocyte hypertrophy, reduce the degree of cardiac fibrosis, and effectively treat pathological myocardial hypertrophy. This invention is the first to demonstrate knockdown... Trmt61a Genes can effectively improve pathological myocardial hypertrophy, providing a new drug development path and target for the prevention and treatment of this disease, and have important medicinal value and clinical application prospects.

The invention provides a traditional Chinese medicine composition for treating heart failure and a preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from the following components: 1-12 parts of rohdea japonica, 1-12 parts of codonopsis pilosula, 1-12 parts of astragalus membranaceus, 1-12 parts of cassia twig, 1-8 parts of bighead atractylodes rhizome, 1-12 parts of poria cocos, 1-12 parts of radix ophiopogonis, 2-14 parts of semen lepidii, 1-10 parts of radix aconiti lateralis preparata, 1-10 parts of schisandra chinensis, 1-12 parts of hairyvein agrimony, 1-10 parts of pseudo-ginseng, 1-12 parts of epimedium, 1-12 parts of leonurus, 1-10 parts of ligusticum wallichii, 2-14 parts of salvia miltiorrhiza, 2-12 parts of radix sophorae flavescentis and 1-8 parts of liquorice. The traditional Chinese medicine composition can enhance myocardial contractility, increase coronary artery blood flow volume, protect myocardial cells, improve heart functions, obviously improve the heart functions and left ventricular remodeling, discharge liquid retained at the time of heart failure, relieve the pre-load of the heart and relieve edema; load during cardiac contraction is reduced, and excessive work of the heart is avoided.

The present invention relates to systems and methods for monitoring impedance from a sensor in the chest of a subject to determine the status of lung inflation or presence of pneumothorax in the subject, the presence of pulmonary edema, the status of regional lung ventilation, and the status of cardiac contractility.

The invention relates to the technical field of biological medicines, in particular to application of an insulin-like growth factor 2 receptor IGF2R inhibitor in preparation of a medicine for preventing and / or treating fulminant myocarditis. The result of the embodiment of the invention shows that the IGF2R expression of the heart tissue is abnormally increased in the state of fulminating myocarditis, and is more obvious in myocardial cells. Expression and / or related biological functions of IGF2R are / is inhibited in a myocardial cell specific mode, the survival outcome of an animal model with fulminating myocarditis can be improved, the systolic and diastolic functions of the heart can be improved, myocardial damage markers are reduced, myocardial tissue inflammatory response is relieved, and the inflammatory factor level is reduced. The application disclosed by the invention is suitable for fulminating myocarditis types including but not limited to viral fulminating myocarditis, and a new intervention strategy and a potential drug target can be provided for the diseases.

The invention discloses an application of a water-soluble fullerene nano material in preparation of a medicine for treating and / or relieving heart failure. The treatment and / or relief of heart failure is embodied in at least one of the following aspects: 1) improving the systolic function of the heart; (2) the increase of the brain natriuretic peptide precursor content caused by heart failure is reduced; (3) the content of Ca < 2 + > in the failure heart is reduced; 4) improving cardiac hypertrophy caused by heart failure; 5) inhibiting cardiac fibrosis caused by heart failure; 6) reducing the active oxygen level of a heart pathologic region; 7) inhibiting inflammation of the heart failure part; and 8) inhibiting pyroptosis, apoptosis and cardiac fibrosis of the heart failure part. In a coronary artery ligation post-myocardial infarction heart failure mouse model, the FPs can regulate redox balance in a pathological area, reduce excessive inflammation, pyroptosis, apoptosis, cardiac hypertrophy and fibrosis of a heart failure part and improve a mouse cardiac systolic function, shows a good treatment effect, and is an ideal medicine for treating heart failure.

A heart phase-locked transcranial magnetic stimulation method and system based on heart-brain axis navigation positioning, the method comprising inputting a preprocessed electrocardiogram signal into a trained and converged TimeMixer model to output a predicted electrocardiogram waveform signal; splicing the predicted electrocardiogram waveform sequence and the original electrocardiogram waveform sequence to obtain a global electrocardiogram sequence, identifying effective R peaks and T wave peaks and determining T wave endpoints on the global electrocardiogram sequence; dividing the systole and diastole of the heart using the effective R peaks and the T wave endpoints, and assigning and encoding the systole and diastole of the heart; determining the target position of the transcranial magnetic stimulation according to the encoding labels corresponding to the systole and diastole of the heart and the transcranial magnetic stimulation target position determined by the heart-brain axis navigation mode, and controlling the parameters of the transcranial magnetic stimulation; by combining the electrocardiogram prediction of the TimeMixer model with the individualized stimulation target point determined by the heart-brain axis navigation, the problems of ignoring individual physiological state in the existing open-loop control, complex closed-loop acquisition being easily disturbed, and inaccurate target point positioning are solved.

The invention discloses application of triethylene tetramine in preparation of a medicine for treating or preventing sepsis complications. Researches show that triethylene tetramine (TETA) can reduce the cardiac systolic function caused by lipopolysaccharide (LPS), and the damage to the mitochondrial structure of myocardial tissue is improved to a certain extent; the TETA also shows that the TETA can improve alveolar interval thickening, pulmonary edema, increase of protein concentration and lactic dehydrogenase activity in alveolar lavage fluid, formation of inflammasome, pyroptosis and the like caused by the LPS to a certain extent; the triethylene tetramine can inhibit expression of inflammatory factors in myocardial tissue and lung tissue, the effect of the triethylene tetramine in treatment or prevention of sepsis complications (sepsis cardiomyopathy and sepsis acute lung injury) is indicated, a new treatment choice is provided for sepsis patients, and the triethylene tetramine has important clinical application value.